The primary objective of this study is to evaluate the efficacy of 6-month treatment with
Advagraf® converted from 12-month treatment with tacrolimus in stable liver transplant
recipients.
The secondary objective of this study is to evaluate severity of acute rejection confirmed by
biopsy in 24 weeks, incidence of chronic rejection, patient and graft survival rates in 24
weeks, incidence of adverse events, blood pressure, tacrolimus trough level, drug compliance,
and adherence.